NCT05756361

Brief Summary

Type 1 Diabetes carries high burden for affected youth and their families. Advances in insulin therapy and technology have been associated with increased obesity with 1/3 adolescents being overweight/obese. Since obesity runs in families and carries risk for poor outcomes psychologically and medically, the investigators are adapting our successful evidence-based Family Based Treatment for hybrid delivery to improve obesity and metabolic control in the affected youth and improve obesity and related co-morbidities in their parents.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
8mo left

Started Apr 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress82%
Apr 2023Dec 2026

First Submitted

Initial submission to the registry

February 9, 2023

Completed
25 days until next milestone

First Posted

Study publicly available on registry

March 6, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

April 26, 2023

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 7, 2025

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Expected
Last Updated

September 16, 2025

Status Verified

September 1, 2025

Enrollment Period

2.2 years

First QC Date

February 9, 2023

Last Update Submit

September 9, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Weight for parent and child

    Participants will be given Body Trace Weight Scales and will weigh themselves twice per week.

    Baseline, 3 and 6 months

Secondary Outcomes (5)

  • Change in insulin dosing

    baseline, 3 and 6 months

  • In parents, change in severity of obesity co-morbidities

    baseline, 3 and 6 months

  • Change in HbA1c

    baseline, 3 and 6 months

  • Change in time in range (TIR) - that is in optimal glycemic range

    baseline, 3 and 6 months

  • In parents, change in medication dosing

    baseline, 3 and 6 months

Study Arms (1)

20 Child-Parent Dyads

EXPERIMENTAL

Family-Based Behavioral Treatment

Behavioral: Family-Based Treatment for T1D

Interventions

Our FBT curriculum, which has been delivered successfully in the specialty and primary care settings, has 3 components: 1. Meal planning including quality of carbohydrates and glycemic index for both parents and children while ensuring that youth have a balanced meal plan with adequate amounts of carbohydrates for optimal growth. Our FBT has a focus on "Food Literacy" including healthy food selection and sourcing of affordable healthy food, food preparation and preplanning, social engagement tailoring the meal plan to the needs to the family in socio cultural appropriate way and also feasibility based on logistics and economic aspects; 2. Physical activity (PA) component with shaping strategy to allow for a progressive shaping of easy PA starting, if needed, with as little as with 10 minutes of walking/day and strategies to incorporate PA in daily routines, family, and social activities; 3. Extensive behavioral component which has been shown to be very powerful in obesity treatment

20 Child-Parent Dyads

Eligibility Criteria

Age6 Years - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • T1D of 12 or more months duration
  • Age 6-17-years
  • Presence of overweight/obesity
  • Youth uses a pump for insulin delivery and a continuous glucose monitoring device to monitor glycemic levels
  • Youth has one parent with overweight/obesity willing to participate in the program

You may not qualify if:

  • Child:
  • Chronic conditions other than T1D
  • Other autoimmune conditions other then T1D or autoimmune thyroiditis.
  • Medications that can affects weight, such as medications used to treat Attention Deficit Disorder or high dose steroids used to treat asthma.
  • Depression symptoms by standard of care Patient Health Questionnaire (PHQ) 9 in the child or parent
  • Inability to perform at least mild physical activity such as walking
  • Child with handicap (such as developmental delay or deafness) that would prevent him/her from benefitting from counseling in person and/or remotely Participating parent with
  • symptoms of depression assessed by standard of care PHQ
  • autoimmune disorders other than T1D or autoimmune thyroiditis
  • Participating parents with chronic disorder that is treated with medications that interfere with weight loss or are preventing him/her from performing at least mild physical activity

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Conventus

Buffalo, New York, 14203, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1Pediatric ObesityOverweight

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesObesityOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 9, 2023

First Posted

March 6, 2023

Study Start

April 26, 2023

Primary Completion

July 7, 2025

Study Completion (Estimated)

December 31, 2026

Last Updated

September 16, 2025

Record last verified: 2025-09

Locations